stockportfolio.pro
LivaNova PLC (LIVN)
Healthcare · Medical Devices · NasdaqGS
LivaNova PLC revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $964.86M | $1.01B | $1.11B | $1.08B | $934.24M | $1.04B | $1.02B | $1.15B | $1.25B | $1.39B |
| Gross profit | $559.51M | $651.62M | $745.64M | $723.80M | $594.76M | $705.99M | $707.23M | $755.82M | $853.48M | $939.87M |
| Net income | $-62.79M | $-25.09M | $-189.40M | $-157.64M | $-348.82M | $-135.82M | $-86.20M | $17.50M | $63.20M | $-242.50M |
| Net margin | -6.5% | -2.5% | -17.1% | -14.5% | -37.3% | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% |
Source: LivaNova PLC SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of LivaNova PLC financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LIVN in your portfolio →
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
LivaNova PLC — frequently asked questions
What is LivaNova PLC's revenue?
LivaNova PLC (LIVN) reported revenue of $1.39B for fiscal year 2025, up 10.7% from the prior year, according to its SEC filings.
Is LivaNova PLC profitable?
No — LIVN reported a net loss of $-242.50M in fiscal 2025.
What is LIVN's P/E ratio?
LivaNova PLC trades at a price-to-earnings ratio of about 39.9 based on the latest data in our nightly-refreshed cache.
How fast is LivaNova PLC growing?
LIVN's revenue grew at roughly 8.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from LivaNova PLC's official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.